PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research3 citations

Decoy-Resistant IL-18 Enhances Checkpoint Inhibitor Activity in Solid Tumor Models

Abstract 4073: Decoy-resistant IL-18 enhances checkpoint inhibitor combinations beyond anti-PD-1 in vitro and in vivo

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJeffrey N. LindquistKQKai QinARAaron M. Ring

Discussion

Loading...

Member takes

Overview

Preclinical study demonstrates enhanced anti-tumor efficacy of decoy-resistant IL-18 with diverse checkpoint inhibitors in tumor models, highlighting therapeutic potential beyond anti-PD-1.

Key Points

  • Decoy-resistant IL-18 monotherapy inhibits tumor growth by over 55% to 80% across murine models, while checkpoint inhibitors combination therapy boosts tumor suppression up to 95%.
  • Preclinical evaluation tested murine decoy-resistant IL-18 alongside anti-PD-1, anti-CTLA-4, or anti-LAG-3 in solid tumors, combined with human ST-067 testing in 3D tumor spheroids.
  • These results demonstrate that decoy-resistant IL-18 circumvents IL-18 binding protein suppression to enhance the tumor microenvironment (mouse model; further preclinical work needed).

Cite This Study

Lindquist et al. (2024) studied this question.

synapsesocial.com/papers/68e72bb1b6db6435876a5e95https://doi.org/10.1158/1538-7445.am2024-4073
View Full Paper
Ask AI
Bookmark
Share